BeiGene, Ltd. to Post Q4 2017 Earnings of ($1.88) Per Share, William Blair Forecasts (BGNE)
BeiGene, Ltd. (NASDAQ:BGNE) – Research analysts at William Blair issued their Q4 2017 EPS estimates for shares of BeiGene in a research note issued to investors on Tuesday. William Blair analyst Y. Xu anticipates that the company will earn ($1.88) per share for the quarter. William Blair also issued estimates for BeiGene’s Q1 2018 earnings at ($2.11) EPS, Q2 2018 earnings at ($2.14) EPS, Q3 2018 earnings at ($2.18) EPS, Q4 2018 earnings at ($1.12) EPS and FY2018 earnings at ($7.56) EPS.
BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the company earned ($1.08) earnings per share.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/18/beigene-ltd-to-post-q4-2017-earnings-of-1-88-per-share-william-blair-forecasts-bgne.html.
Several other equities research analysts have also recently weighed in on BGNE. Ladenburg Thalmann Financial Services started coverage on shares of BeiGene in a research note on Monday, August 7th. They issued a “buy” rating and a $81.00 target price for the company. Zacks Investment Research cut shares of BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. The Goldman Sachs Group, Inc. restated a “buy” rating and set a $86.00 price target (up previously from $43.00) on shares of BeiGene in a research note on Tuesday, August 15th. Maxim Group restated a “buy” rating and set a $77.00 price target on shares of BeiGene in a research note on Monday, September 11th. Finally, Morgan Stanley restated an “overweight” rating and set a $95.00 price target (up previously from $87.00) on shares of BeiGene in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $96.67.
Shares of BeiGene (NASDAQ BGNE) opened at $84.18 on Friday. The company has a current ratio of 8.38, a quick ratio of 8.38 and a debt-to-equity ratio of 0.57. BeiGene has a one year low of $26.43 and a one year high of $118.95.
In related news, CMO Amy C. Peterson sold 3,601 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $82.96, for a total value of $298,738.96. Following the sale, the chief marketing officer now directly owns 1,201 shares of the company’s stock, valued at approximately $99,634.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Oyler sold 150,957 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares in the company, valued at $39,597,225.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 179,612 shares of company stock worth $14,531,763. Insiders own 19.90% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of BGNE. SG Americas Securities LLC acquired a new stake in BeiGene in the 2nd quarter valued at $111,000. Quantbot Technologies LP acquired a new stake in BeiGene in the 3rd quarter valued at $160,000. Renaissance Technologies LLC acquired a new stake in BeiGene in the 1st quarter valued at $238,000. Profund Advisors LLC acquired a new stake in BeiGene in the 2nd quarter valued at $248,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in BeiGene in the 3rd quarter valued at $248,000. 52.09% of the stock is currently owned by institutional investors and hedge funds.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.